119 related articles for article (PubMed ID: 30342000)
21. A 10-year analysis of primary cutaneous malignant melanoma with sentinel lymph node biopsy and long-term follow-up.
Beger J; Hansel G; Krönert C; Fuchs M; Tanner C; Schönlebe J; Werner C; Nowak A; Haroske G; Witzigmann H; Wollina U
Int J Dermatol; 2013 Feb; 52(2):220-30. PubMed ID: 23347311
[TBL] [Abstract][Full Text] [Related]
22. Highly sensitive multivariable assay detection of melanocytic differentiation antigens and angiogenesis biomarkers in sentinel lymph nodes with melanoma micrometastases.
Vitoux D; Mourah S; Kerob D; Verola O; Basset-Seguin N; Baccard M; Schartz N; Ollivaud L; Archimbaud A; Servant JM; Revol M; Toubert ME; Podgorniak MP; Plassa F; Porcher R; Lebbé C
Arch Dermatol; 2009 Oct; 145(10):1105-13. PubMed ID: 19841396
[TBL] [Abstract][Full Text] [Related]
23. Novel role for RGS1 in melanoma progression.
Rangel J; Nosrati M; Leong SP; Haqq C; Miller JR; Sagebiel RW; Kashani-Sabet M
Am J Surg Pathol; 2008 Aug; 32(8):1207-12. PubMed ID: 18580492
[TBL] [Abstract][Full Text] [Related]
24. Clinical and histopathological risk factors to predict sentinel lymph node positivity, disease-free and overall survival in clinical stages I-II AJCC skin melanoma: outcome analysis from a single-institution prospectively collected database.
Mandalà M; Imberti GL; Piazzalunga D; Belfiglio M; Labianca R; Barberis M; Marchesi L; Poletti P; Bonomi L; Novellino L; Di Biagio K; Milesi A; Guerra U; Tondini C
Eur J Cancer; 2009 Sep; 45(14):2537-45. PubMed ID: 19553103
[TBL] [Abstract][Full Text] [Related]
25. Diagnostic and prognostic role of galectin 3 expression in cutaneous melanoma.
Abdou AG; Hammam MA; Farargy SE; Farag AG; El Shafey EN; Farouk S; Elnaidany NF
Am J Dermatopathol; 2010 Dec; 32(8):809-14. PubMed ID: 20885286
[TBL] [Abstract][Full Text] [Related]
26. Worse outcome for patients with recurrent melanoma after negative sentinel lymph biopsy as compared to sentinel-positive patients.
Gambichler T; Scholl L; Bechara FG; Stockfleth E; Stücker M
Eur J Surg Oncol; 2016 Sep; 42(9):1420-6. PubMed ID: 27160354
[TBL] [Abstract][Full Text] [Related]
27. Survival analysis and clinicopathological factors associated with false-negative sentinel lymph node biopsy findings in patients with cutaneous melanoma.
Nowecki ZI; Rutkowski P; Nasierowska-Guttmejer A; Ruka W
Ann Surg Oncol; 2006 Dec; 13(12):1655-63. PubMed ID: 17016755
[TBL] [Abstract][Full Text] [Related]
28. Sentinel lymph node biopsy for 102 patients with primary cutaneous melanoma at a single Japanese institute.
Otsuka M; Yamasaki O; Kaji T; Iwatsuki K; Asagoe K
J Dermatol; 2015 Oct; 42(10):954-61. PubMed ID: 26074328
[TBL] [Abstract][Full Text] [Related]
29. Pigmentation in the sentinel node correlates with increased sentinel node tumor burden in melanoma patients.
van Lanschot CG; Koljenović S; Grunhagen DJ; Verhoef C; van Akkooi AC
Melanoma Res; 2014 Jun; 24(3):261-6. PubMed ID: 24608184
[TBL] [Abstract][Full Text] [Related]
30. Predictors of sentinel lymph node positivity in thin melanoma using the National Cancer Database.
Conic RRZ; Ko J; Damiani G; Funchain P; Knackstedt T; Vij A; Vidimos A; Gastman BR
J Am Acad Dermatol; 2019 Feb; 80(2):441-447. PubMed ID: 30240775
[TBL] [Abstract][Full Text] [Related]
31. PD-L1 expression in tumour-infiltrating lymphocytes is a poor prognostic factor for primary acral melanoma patients.
Ren M; Dai B; Kong YY; Lv JJ; Cai X
Histopathology; 2018 Sep; 73(3):386-396. PubMed ID: 29637587
[TBL] [Abstract][Full Text] [Related]
32. Dermal melanoma: A report on prognosis, outcomes, and the utility of sentinel lymph node biopsy.
Doepker MP; Thompson ZJ; Harb JN; Messina JL; Puleo CA; Egan KM; Sarnaik AA; Gonzalez RJ; Sondak VK; Zager JS
J Surg Oncol; 2016 Jan; 113(1):98-102. PubMed ID: 26661407
[TBL] [Abstract][Full Text] [Related]
33. Sentinel lymph node biopsy is accurate and prognostic in head and neck melanoma.
Erman AB; Collar RM; Griffith KA; Lowe L; Sabel MS; Bichakjian CK; Wong SL; McLean SA; Rees RS; Johnson TM; Bradford CR
Cancer; 2012 Feb; 118(4):1040-7. PubMed ID: 21773971
[TBL] [Abstract][Full Text] [Related]
34. Cancer-testis antigen expression in primary cutaneous melanoma has independent prognostic value comparable to that of Breslow thickness, ulceration and mitotic rate.
Svobodová S; Browning J; MacGregor D; Pollara G; Scolyer RA; Murali R; Thompson JF; Deb S; Azad A; Davis ID; Cebon JS
Eur J Cancer; 2011 Feb; 47(3):460-9. PubMed ID: 21115342
[TBL] [Abstract][Full Text] [Related]
35. Is there a benefit to sentinel lymph node biopsy in patients with T4 melanoma?
Gajdos C; Griffith KA; Wong SL; Johnson TM; Chang AE; Cimmino VM; Lowe L; Bradford CR; Rees RS; Sabel MS
Cancer; 2009 Dec; 115(24):5752-60. PubMed ID: 19827151
[TBL] [Abstract][Full Text] [Related]
36. Sentinel node biopsy in melanoma delays recurrence but does not change melanoma-related survival: a retrospective analysis of 673 patients.
Gutzmer R; Al Ghazal M; Geerlings H; Kapp A
Br J Dermatol; 2005 Dec; 153(6):1137-41. PubMed ID: 16307648
[TBL] [Abstract][Full Text] [Related]
37. Defining the role of CD2 in disease progression and overall survival among patients with completely resected stage-II to -III cutaneous melanoma.
Harcharik S; Bernardo S; Moskalenko M; Pan M; Sivendran M; Bell H; Hall LD; Castillo-Martín M; Fox K; Cordon-Cardo C; Chang R; Sivendran S; Phelps RG; Saenger Y
J Am Acad Dermatol; 2014 Jun; 70(6):1036-44. PubMed ID: 24698703
[TBL] [Abstract][Full Text] [Related]
38. Paucity of tumor-infiltrating lymphocytes is an unfavorable prognosticator and predicts lymph node metastases in cutaneous melanoma patients.
Donizy P; Kaczorowski M; Halon A; Leskiewicz M; Kozyra C; Matkowski R
Anticancer Res; 2015 Jan; 35(1):351-8. PubMed ID: 25550571
[TBL] [Abstract][Full Text] [Related]
39. Prognostic role of sentinel lymph node biopsy for patients with cutaneous melanoma: A retrospective study of surveillance, epidemiology, and end-result population-based data.
Chen J; Xu Y; Zhou Y; Wang Y; Zhu H; Shi Y
Oncotarget; 2016 Jul; 7(29):45671-45677. PubMed ID: 27344178
[TBL] [Abstract][Full Text] [Related]
40. PARP1 as a Marker of an Aggressive Clinical Phenotype in Cutaneous Melanoma-A Clinical and an In Vitro Study.
Kupczyk P; Simiczyjew A; Marczuk J; Dratkiewicz E; Beberok A; Rok J; Pieniazek M; Biecek P; Nevozhay D; Slowikowski B; Chodaczek G; Wrzesniok D; Nowak D; Donizy P
Cells; 2021 Jan; 10(2):. PubMed ID: 33572647
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
